Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease

Huntington disease (HD) is an adult onset neurodegenerative disorder characterized by selective atrophy and cell loss within the striatum. There is currently no treatment that can prevent the striatal neuropathology. Transglutaminase (TG) activity is increased in HD patients, is associated with cell death, and has been suggested to contribute to striatal neuronal loss in HD. This work assesses the therapeutic potential of cystamine, an inhibitor of TG activity with additional potentially beneficial effects. Specifically, we examine the effect of cystamine on striatal neuronal loss in the YAC128 mouse model of HD. We demonstrate here for the first time that YAC128 mice show a forebrain‐specific increase in TG activity compared with wild‐type (WT) littermates which is decreased by oral delivery of cystamine. Treatment of symptomatic YAC128 mice with cystamine starting at 7 months prevented striatal neuronal loss. Cystamine treatment also ameliorated the striatal volume loss and striatal neuronal atrophy observed in these animals, but was unable to prevent motor dysfunction or the down‐regulation of dopamine and cyclic adenosine monophsophate‐regulated phosphoprotein (DARPP‐32) expression in the striatum. While the exact mechanism responsible for the beneficial effects of cystamine in YAC128 mice is uncertain, our findings suggest that cystamine is neuroprotective and may be beneficial in the treatment of HD.

[1]  P. Matarrese,et al.  Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress , 2002, Journal of neurochemistry.

[2]  S. Tsuji,et al.  Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch , 1998, Nature Genetics.

[3]  M. Hayden,et al.  Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[4]  Does tissue transglutaminase play a role in Huntington's disease? , 2002, Neurochemistry International.

[5]  G. Melino,et al.  Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells , 1994, Molecular and cellular biology.

[6]  C. Ross,et al.  Mutant Huntingtin Protein: A Substrate for Transglutaminase 1, 2, and 3 , 2005, Journal of neuropathology and experimental neurology.

[7]  Sawsan Youssef,et al.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine , 2002, Nature Medicine.

[8]  S. Hersch,et al.  Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease , 2002, The Journal of Neuroscience.

[9]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[10]  C. Rodolfo,et al.  Inhibition of “Tissue” Transglutaminase Increases Cell Survival by Preventing Apoptosis* , 1999, The Journal of Biological Chemistry.

[11]  R. Graham,et al.  Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases , 2004, Molecular and Cellular Neuroscience.

[12]  M. Hayden,et al.  Treatment of YAC128 mice and their wild‐type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease , 2005, Journal of neurochemistry.

[13]  G. Li Volti,et al.  Cystamine inhibits transglutaminase and caspase‐3 cleavage in glutamate‐exposed astroglial cells , 2003, Journal of neuroscience research.

[14]  S. Oiki,et al.  Paradoxical Inhibition of Protein Aggregation and Precipitation by Transglutaminase-catalyzed Intermolecular Cross-linking* , 2005, Journal of Biological Chemistry.

[15]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[16]  M. Beal,et al.  N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. , 2001, Journal of neurochemistry.

[17]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[18]  J. Burke,et al.  Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats , 2004, Journal of neurochemistry.

[19]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[20]  G. Melino,et al.  ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease , 2002, Cell Death and Differentiation.

[21]  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2003 .

[22]  J. Blass,et al.  Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG) n /Q n -expansion diseases? , 2002, Neurochemistry International.

[23]  G. Halliday,et al.  Pyramidal Cell Loss in Motor Cortices in Huntington's Disease , 2002, Neurobiology of Disease.

[24]  T. de Cristofaro,et al.  The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates. , 1999, Biochemical and biophysical research communications.

[25]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[26]  Angus C Nairn,et al.  DARPP-32: an integrator of neurotransmission. , 2004, Annual review of pharmacology and toxicology.

[27]  S. Hersch,et al.  Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation , 2004, Journal of neurochemistry.

[28]  R. Ferrante,et al.  Tissue Transglutaminase Is Increased in Huntington's Disease Brain , 1999, Journal of neurochemistry.

[29]  L. Steinman,et al.  Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications , 2002, Neurochemistry International.

[30]  Arthur James Cooper,et al.  Transglutaminases - possible drug targets in human diseases. , 2004, Current drug targets. CNS and neurological disorders.

[31]  M. Beal,et al.  N ε ‐(γ‐l‐Glutamyl)‐l‐lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease , 2001 .

[32]  Shin-ichi Sato,et al.  Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. , 2005, Biochemistry.

[33]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[34]  C. Ross,et al.  Tissue Transglutaminase Does Not Contribute to the Formation of Mutant Huntingtin Aggregates , 2001, The Journal of cell biology.

[35]  James E Bear,et al.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Roses,et al.  Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Johnson,et al.  The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase , 2006, Neurobiology of Aging.

[38]  C. Ross,et al.  Transglutaminase Cross‐Links in Intranuclear Inclusions in Huntington Disease , 2003, Journal of neuropathology and experimental neurology.

[39]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[40]  G. Johnson,et al.  Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate‐independent mechanisms , 2005, Journal of neurochemistry.

[41]  H. Green.  Human genetic diseases due to codon reiteration: Relationship to an evolutionary mechanism , 1993, Cell.

[42]  H. Green,et al.  Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. , 1998, Molecular cell.